BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» ZSTK-3744 overcomes chemotherapy resistance in TNBC
To read the full story,
subscribe
or
sign in
.
Cancer
ZSTK-3744 overcomes chemotherapy resistance in TNBC
Feb. 13, 2026
No Comments
Researchers from Zenyaku Kogyo Co. Ltd. reported the preclinical efficacy profile of ZSTK-3744, an aryl hydrocarbon receptor (AHR) agonist.
BioWorld Science
Cancer
